arrow
D

Dhan Chand

university of texas system
H指数:16
被引数:1,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses

胶质瘤-内在MAPK/ERK信号通过T细胞浸润和干扰素反应促进免疫治疗效果

2026-06-250
OAAI
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma

一项关于博腾司利单抗和巴腾司利单抗治疗难治性肝细胞癌的Phase 1b期研究

2026-03-011
PRE
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling

抗PD-L2免疫疗法通过IL-17和IFNγ信号通路对老年宿主中的黑色素瘤具有疗效。

2025-11-190
OAAI
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference

放射治疗-免疫治疗联合疗法的最新进展:第8届年度免疫放射大会会议录

2025-05-220
OAAI
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024-07-311
OAAI
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas
2024-07-191
PRE
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
2024-06-1310
OAAI
MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy, effectively treats human organoid models of treatment-refractory MSS colorectal cancer (CRC) liver metastases
2024-03-220
PRE
BMS-986442 ( AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
2024-03-220
PRE
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

中重度急性呼吸窘迫综合征不变自然杀伤T细胞治疗的1/2期临床试验

2024-02-066
OAAI
Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors
2020-08-150
PRE